Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Public ClinicalTrials.gov record NCT03418038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Study identification
- NCT ID
- NCT03418038
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Ascorbic Acid Dietary Supplement
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Carboplatin Drug
- Central Venous Cannula Insertion Procedure
- Cisplatin Drug
- Computed Tomography Procedure
- Core Biopsy Procedure
- Cytarabine Drug
- Decitabine Drug
- Dexamethasone Drug
- Echocardiography Procedure
- Etoposide Drug
- Gemcitabine Hydrochloride Drug
- Ifosfamide Drug
- Laboratory Biomarker Analysis Other
- Magnetic Resonance Imaging Procedure
- Oxaliplatin Drug
- Placebo Administration Other
- Portacath Placement Procedure
- Positron Emission Tomography Procedure
- Questionnaire Administration Other
- Rituximab Biological
Dietary Supplement · Procedure · Drug + 2 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 22, 2018
- Primary completion
- Feb 21, 2031
- Completion
- Nov 1, 2033
- Last update posted
- Apr 15, 2026
2018 – 2033
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Health Systems-Mankato | Mankato | Minnesota | 56001 | Not yet recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Mayo Clinic Health System-Eau Claire Clinic | Eau Claire | Wisconsin | 54701 | Not yet recruiting |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | 54601 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03418038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03418038 live on ClinicalTrials.gov.